Welcome to
synapcell blog
Why Preclinical EEG Biomarkers?
Modified electrical activity in neuronal networks is symptomatic of a wide range of CNS disorders. Local Field Potentials (LFP) are recorded in vivo by EEG, in the brain of freely-moving, translational models. These oscillations offer a direct window on neuronal networks activity.
Disease-specific EEG signatures can be used as surrogate Biomarkers to assess your compounds effects in vivo, longitudinally. Drawing on a unique expertise built on 20 years of experience in the field, our EEG Biomarker approach delivers smooth human-rodent translation, high reproducibility levels and robust endpoints, particularly well-suited to evaluate your compounds effects with no bias.
Back Translate from Bedside to Bench
We are taking advantage of the brain evolutionary conserved electrical functions to measure a compound effect on disease-specific brain oscillations. Inspired by the state-of-the-art clinical research, our experts identify translational EEG biomarkers for drug discovery applications. This is what makes our approach unique.
Objective Measures of Investigational Compound Efficacy
As a tried and true method, EEG is routinely used in the clinical practice. It represents a direct window on brain function with high time resolution and great sensitivity. EEG-based, our Cue® technology measures neural activity in an objective and precise way, offering at the same time reproducibility of the results. Get deeper insights into the pharmacological efficacy of new CNS drug candidates with readouts that smoothly translate.
Robust Statistics
Our full solution adresses one of the most critical aspects of current studies: Getting results with high statistical power. Crossover protocols, high precision level of EEG measures, offer reproducibility and significant results that stand out, so you can secure the next steps with your investigational compound.
Brain Activity at Subclinical Thresholds
See what you couldn’t before. Our expert services and support make it possible to consider early diagnostic and neuroprotective strategies, by giving you significant information on disease processes that had remained unaccessible until now.
Translationally Predictive
Our translational approach connects preclinical and clinical development phases. All experiments performed for you follow clinical protocols and include models that mirror human diseases. Therefore, the preclinical EEG biomarkers identified can predict the impact your molecule may have through the different clinical phases.